What would be a rare complication of magnesium sulfate treatment in a patient with myasthenia gravis?

Magnesium sulfate is often used in various clinical settings, including for the treatment of severe asthma or as a tocolytic agent in preterm labor. In patients with myasthenia gravis, a condition characterized by weakness in voluntary muscles, the effects of magnesium can be particularly pronounced.

When magnesium is administered, it can cause neuromuscular transmission issues, which may exacerbate the symptoms of myasthenia gravis. This is due to magnesium's action as a neuromuscular blocking agent, which can interfere with the release of acetylcholine at the neuromuscular junction and lead to increased weakness or even a crisis.

Magnesium toxicity, specifically in this context, refers to an overload of magnesium in the body due to its pharmacological effects, especially in those patients already predisposed to neuromuscular impairment. This condition can manifest as profound muscle weakness, respiratory failure, or even crisis, making it an important consideration.

While other complications can occur with magnesium sulfate treatment, such as respiratory failure or cardiac arrest, these are not as specific to myasthenia gravis as magnesium toxicity leading to crisis. Thus, the rare complication of magnesium sulfate treatment specifically in a patient with myasthenia grav